ATLANTA, GA -- (MARKET WIRE) -- November 07, 2006 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it named J. Christopher Prue, RPh to the position of Vice President, Regulatory Affairs. Mr. Prue will report to Dr. Rob Scott, AtheroGenics’ Executive Vice President, Research and Development and Chief Medical Officer. Additionally, Ross Raymond was appointed Senior Director, Regulatory Affairs and Regulatory Information Systems, and he will report to Mr. Chris Prue.
